Fagron Expands U.S. Compounding Platform With UCP Deal
Nazareth, Belgium / Rotterdam, Netherlands | January 12, 2026 — Fagron has completed the acquisition of University Compounding Pharmacy...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Nazareth, Belgium / Rotterdam, Netherlands | January 12, 2026 — Fagron has completed the acquisition of University Compounding Pharmacy...
Bagsværd, Denmark & South San Francisco, CA — December 9, 2025 — Novo Nordisk has officially completed its acquisition...
AUSTIN, Texas — December 5, 2025 — Natera has announced the acquisition of Foresight Diagnostics, a precision oncology company...
New York, October 30, 2025 — Pfizer Inc. (NYSE: PFE) has issued a strong response to what it calls...
Basel, Switzerland – October 30, 2025 — Roche Holding AG (SIX: RO, ROG; OTCQX: RHHBY) has successfully completed its...
ABU DHABI, UAE, Oct. 7, 2025 — PureHealth Holding PJSC announced the completion of its €800 million acquisition of...
Hayward, CA – September 9, 2025 – Pulse Biosciences, a pioneer in bioelectric medicine and nanosecond pulsed field ablation...
September 9, 2025 – Basel – In a move set to strengthen its cardiovascular disease portfolio, Novartis announced an...
